Lexaria Bioscience Corp. (LEXX)

Lexaria Bioscience Income Statement

Financials in millions USD. Fiscal year is September - August.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug 31, 2025	Aug 31, 2024	Aug 31, 2023	Aug 31, 2022	Aug 31, 2021
Revenue	0.71	0.46	0.23	0.26	0.72
Revenue Growth (YoY)	52.05%	105.24%	-11.43%	-64.66%	129.59%
Cost of Revenue	0	0	0.03	0.07	0.18
Gross Profit	0.7	0.46	0.19	0.18	0.55
Selling, General & Admin	4.1	3.79	2.96	4.96	4.97
Research & Development	8.24	2.36	3.67	1.84	1.26
Operating Expenses	12.34	6.15	6.62	6.8	6.23
Operating Income	-11.63	-5.7	-6.43	-6.62	-5.69
Interest & Investment Income	0	0.01	0.04	-	-
EBT Excluding Unusual Items	-11.63	-5.68	-6.38	-6.62	-5.69
Gain (Loss) on Sale of Investments	-0.03	-0.07	-0.22	-0.76	-
Asset Writedown	-0.25	-0.06	-0.11	-	-
Pretax Income	-11.91	-5.81	-6.71	-7.38	-5.69
Earnings From Continuing Operations	-11.91	-5.81	-6.71	-7.38	-5.69
Earnings From Discontinued Operations	-	-	-	-	1.5
Net Income to Company	-11.91	-5.81	-6.71	-7.38	-4.19
Minority Interest in Earnings	0.01	0.01	0.05	0.11	0.16
Net Income	-11.9	-5.8	-6.66	-7.27	-4.03
Net Income to Common	-11.9	-5.8	-6.66	-7.27	-4.03
Shares Outstanding (Basic)	18	12	7	6	4
Shares Outstanding (Diluted)	18	12	7	6	4
Shares Change (YoY)	45.34%	87.24%	12.38%	34.02%	58.34%
EPS (Basic)	-0.66	-0.47	-1.01	-1.24	-0.92
EPS (Diluted)	-0.66	-0.47	-1.01	-1.24	-0.92
Free Cash Flow	-10.48	-5	-5.91	-4.93	-3.99
Free Cash Flow Per Share	-0.58	-0.40	-0.89	-0.84	-0.91
Gross Margin	99.61%	98.96%	86.08%	71.87%	75.74%
Operating Margin	-1647.97%	-1226.70%	-2841.31%	-2591.67%	-786.85%
Profit Margin	-1686.00%	-1248.25%	-2946.36%	-2846.28%	-557.19%
Free Cash Flow Margin	-1483.88%	-1077.38%	-2614.84%	-1929.75%	-552.02%
EBITDA	-11.55	-5.62	-6.28	-6.52	-5.58
D&A For EBITDA	0.09	0.08	0.15	0.1	0.11
EBIT	-11.63	-5.7	-6.43	-6.62	-5.69

Updated Aug 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q